Clinical Trial

OSU6162 in Bipolar Depression (OBID)

Study acronym: OBID
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in subjects with bipolar depression. The study will consist of 9 visits and 1 safety visit. Subjects with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-03-24; most recent amendment 2025-03-19.
Trial Details
NCT Number NCT05296356
Lead Sponsor Göteborg University
Collaborators: Arvid Carlsson Research AB
Conditions Bipolar Depression
Enrollment 22 participants
Start Date 2021-10-25
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-21